Polymorphisms in Th1/Th2 cytokine Genes, hormone replacement therapy, and risk of non-Hodgkin lymphoma
AbstractWe conducted a population-based case-control study in Connecticut women to test the hypothesis that genetic variations in Th1 and Th2 cytokine genes modify the relationship between hormone replacement therapy (HRT) and risk of non-Hodgkin lymphoma (NHL). Compared to women without a history o...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2011-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00021/full |
| _version_ | 1811268529811357696 |
|---|---|
| author | Gongjian eZhu Gongjian eZhu Dongsheng ePan Dongsheng ePan Tongzhang eZheng Qing eLan Xuezhong eChen Xuezhong eChen Yingtai eChen Yingtai eChen Christopher eKim Xiaofeng eBi Xiaofeng eBi Theodore eHolford Peter eBoyle Brian eLeaderer Stephen eChanock Nathaniel eRothman Yawei eZhang |
| author_facet | Gongjian eZhu Gongjian eZhu Dongsheng ePan Dongsheng ePan Tongzhang eZheng Qing eLan Xuezhong eChen Xuezhong eChen Yingtai eChen Yingtai eChen Christopher eKim Xiaofeng eBi Xiaofeng eBi Theodore eHolford Peter eBoyle Brian eLeaderer Stephen eChanock Nathaniel eRothman Yawei eZhang |
| author_sort | Gongjian eZhu |
| collection | DOAJ |
| description | AbstractWe conducted a population-based case-control study in Connecticut women to test the hypothesis that genetic variations in Th1 and Th2 cytokine genes modify the relationship between hormone replacement therapy (HRT) and risk of non-Hodgkin lymphoma (NHL). Compared to women without a history of HRT use, women with a history of HRT use had a significantly decreased risk of NHL if they carried IFNGR2 (rs1059293) CT/TT genotypes (OR=0.5, 95%CI: 0.3-0.9), IL13 (rs20541) GG genotype (OR=0.6, 95%CI: 0.4-0.9) and IL13 (rs1295686) CC genotype (OR=0.6, 95%CI: 0.4-0.8), but not among women who carried IFNGR2 CC, IL13 AG /AA and IL13 CT/TT genotypes. A similar pattern was also observed for B-cell lymphoma but not for T-cell lymphoma. A statistically significant interaction was observed for IFNGR2 (rs1059293 Pforinteraction=0.024), IL13 (rs20541 Pforinteraction=0.005), IL13 (rs1295686 Pforinteraction=0.008) and IL15RA (rs2296135 Pforinteraction=0.049) for NHL overall; IL13 (rs20541 Pforinteraction=0.0009), IL13 (rs1295686 Pforinteraction=0.0002), and IL15RA (rs2296135 Pforinteraction=0.041) for B-cell lymphoma. The results suggest that common genetic variation in Th1/Th2 pathway genes may modify the association between HRT and NHL risk. |
| first_indexed | 2024-04-12T21:24:47Z |
| format | Article |
| id | doaj.art-9243a6710cef4495a664f2003910de3a |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T21:24:47Z |
| publishDate | 2011-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-9243a6710cef4495a664f2003910de3a2022-12-22T03:16:12ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2011-07-01110.3389/fonc.2011.0002111248Polymorphisms in Th1/Th2 cytokine Genes, hormone replacement therapy, and risk of non-Hodgkin lymphomaGongjian eZhu0Gongjian eZhu1Dongsheng ePan2Dongsheng ePan3Tongzhang eZheng4Qing eLan5Xuezhong eChen6Xuezhong eChen7Yingtai eChen8Yingtai eChen9Christopher eKim10Xiaofeng eBi11Xiaofeng eBi12Theodore eHolford13Peter eBoyle14Brian eLeaderer15Stephen eChanock16Nathaniel eRothman17Yawei eZhang18Gansu Provincial Academy of Medical SciencesYale UniversityGansu Provincial Tumor HospitalYale UniversityYale UniversityNational Cancer InstituteGansu Provincial Academy of Medical SciencesGansu Provincial Tumor HospitalCancer Institute/Hospital, Chinese Academy of Medical SciencesYale UniversityYale UniversityCancer Institute/Hospital, Chinese Academy of Medical SciencesYale UniversityYale UniversityInternational Preventive Research InstituteYale UniversityNational Cancer InstituteNational Cancer InstituteYale UniversityAbstractWe conducted a population-based case-control study in Connecticut women to test the hypothesis that genetic variations in Th1 and Th2 cytokine genes modify the relationship between hormone replacement therapy (HRT) and risk of non-Hodgkin lymphoma (NHL). Compared to women without a history of HRT use, women with a history of HRT use had a significantly decreased risk of NHL if they carried IFNGR2 (rs1059293) CT/TT genotypes (OR=0.5, 95%CI: 0.3-0.9), IL13 (rs20541) GG genotype (OR=0.6, 95%CI: 0.4-0.9) and IL13 (rs1295686) CC genotype (OR=0.6, 95%CI: 0.4-0.8), but not among women who carried IFNGR2 CC, IL13 AG /AA and IL13 CT/TT genotypes. A similar pattern was also observed for B-cell lymphoma but not for T-cell lymphoma. A statistically significant interaction was observed for IFNGR2 (rs1059293 Pforinteraction=0.024), IL13 (rs20541 Pforinteraction=0.005), IL13 (rs1295686 Pforinteraction=0.008) and IL15RA (rs2296135 Pforinteraction=0.049) for NHL overall; IL13 (rs20541 Pforinteraction=0.0009), IL13 (rs1295686 Pforinteraction=0.0002), and IL15RA (rs2296135 Pforinteraction=0.041) for B-cell lymphoma. The results suggest that common genetic variation in Th1/Th2 pathway genes may modify the association between HRT and NHL risk.http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00021/fullpolymorphismsnon-Hodgkin lymphomaHRTTh1/Th2 cytokine gene |
| spellingShingle | Gongjian eZhu Gongjian eZhu Dongsheng ePan Dongsheng ePan Tongzhang eZheng Qing eLan Xuezhong eChen Xuezhong eChen Yingtai eChen Yingtai eChen Christopher eKim Xiaofeng eBi Xiaofeng eBi Theodore eHolford Peter eBoyle Brian eLeaderer Stephen eChanock Nathaniel eRothman Yawei eZhang Polymorphisms in Th1/Th2 cytokine Genes, hormone replacement therapy, and risk of non-Hodgkin lymphoma Frontiers in Oncology polymorphisms non-Hodgkin lymphoma HRT Th1/Th2 cytokine gene |
| title | Polymorphisms in Th1/Th2 cytokine Genes, hormone replacement therapy, and risk of non-Hodgkin lymphoma |
| title_full | Polymorphisms in Th1/Th2 cytokine Genes, hormone replacement therapy, and risk of non-Hodgkin lymphoma |
| title_fullStr | Polymorphisms in Th1/Th2 cytokine Genes, hormone replacement therapy, and risk of non-Hodgkin lymphoma |
| title_full_unstemmed | Polymorphisms in Th1/Th2 cytokine Genes, hormone replacement therapy, and risk of non-Hodgkin lymphoma |
| title_short | Polymorphisms in Th1/Th2 cytokine Genes, hormone replacement therapy, and risk of non-Hodgkin lymphoma |
| title_sort | polymorphisms in th1 th2 cytokine genes hormone replacement therapy and risk of non hodgkin lymphoma |
| topic | polymorphisms non-Hodgkin lymphoma HRT Th1/Th2 cytokine gene |
| url | http://journal.frontiersin.org/Journal/10.3389/fonc.2011.00021/full |
| work_keys_str_mv | AT gongjianezhu polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT gongjianezhu polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT dongshengepan polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT dongshengepan polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT tongzhangezheng polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT qingelan polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT xuezhongechen polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT xuezhongechen polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT yingtaiechen polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT yingtaiechen polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT christopherekim polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT xiaofengebi polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT xiaofengebi polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT theodoreeholford polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT petereboyle polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT brianeleaderer polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT stephenechanock polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT nathanielerothman polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma AT yaweiezhang polymorphismsinth1th2cytokinegeneshormonereplacementtherapyandriskofnonhodgkinlymphoma |